Skip to main content
. 2023 Mar 13;19(6):1731–1747. doi: 10.7150/ijbs.78554

Figure 2.

Figure 2

Effect of the combination of CM728 and standard of care drugs on in vitro and in vivo models of TNBC. A-B, Cells were treated with CM728 in combination with DXT (A) or PXT (B) for 48 h (MDA-MB-231 and Hs578T) or 72 h (BT-549). MTT metabolism assays were performed and analyzed using Chou-Talalay algorithm to obtain the combination index (n=2). C, Analysis of the growth of MDA-MB-231 xenograft tumors in response to vehicle, CM728, DXT, or the combination of CM728 and DXT (left), and monitoring of mice body weight (right) (n= 8 mice per group). CM728 (5-10 mg/kg) was administered orally 6 days/week and DXT (10 mg/kg) was injected into the intraperitoneal cavity 1 day/week. Statistical analyses were conducted using one-way ANOVA, and Tukey's multiple comparison test. Comparisons versus control (endpoint): CM728, P = 0.0002; DXT, P < 0.0001; CM728-DXT, P < 0.0001. Comparisons versus CM728 (endpoint): DXT, P = 0.0119; CM728-DXT, P < 0.0001. Comparisons versus DXT (endpoint): CM728-DXT, P = 0.0306.